Generic drugmaker Sandoz files anti-dumping complaint about Chinese antibiotics imports
Generic drugmaker Sandoz files anti-dumping complaint about Chinese antibiotics imports ZURICH, May 28 (Reuters) - Swiss generic drugmaker Sandoz SDZ.S filed a draft anti-dumping complaint with the European Commission over Chinese imports of the antibiotic ingredient amoxicillin, part of the penicillin family, the company said on Thursday.
Sandoz says it has the only major remaining vertically integrated production network for penicillins in Europe.
Sandoz says Chinese market-distorting behaviours include sustained below-cost pricing, state subsidies and concentration of global capacity in China.
Chief Executive Richard Saynor said Europe risks losing antibiotic manufacturing capacity, saying that up to 90% of global antibiotic active ingredients are now produced outside Europe.
"Safeguarding antibiotic supply is not only a health policy issue, but a question of economic security and strategic trade policy. Europe must act now to safeguard independent supply in years to come," Saynor said in the statement.
(Reporting by Marleen Kaesebier in Zurich
Editing by Matthew Lewis)
((marleen.kaesebier@thomsonreuters.com;))
Recent news on Sandoz AG
See all newsPfizer dismissed from US states' drug price-fixing lawsuit (updated)
Pfizer dismissed from US states' drug price-fixing lawsuit
Factbox: Major investment pledges at Choose France summit
Press Digest: Financial Times - June 1
Media: Sandoz warns cheap Chinese imports threaten Europe’s antibiotic supply- FT